We are excited to announce an expanded indication in the US! Read the full press release here: https://bit.ly/41MiKJU
About us
Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare MC4R pathway diseases. The company is leveraging the Rhythm Engine -- comprised of its TEMPO Registry, GO-ID genotyping study and Uncovering Rare Obesity program -- to improve the understanding, diagnosis and potentially the treatment of these disorders. For healthcare professionals, visit www.RareObesity.com for more information. For patients and caregivers, visit www.LEADforRareObesity.com for more information.
- Website
-
http://www.rhythmtx.com
External link for Rhythm Pharmaceuticals Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, MA
- Type
- Public Company
- Founded
- 2008
- Specialties
- genetics, obesity, peptides, metabolism, rare disease, biotechnology, Pharmaceuticals, Research, Health, Medicine, Clinical Trials, Endocrinology, Orphan disease, Science, Advocacy, Epidemiology, Orphan drugs, Rare disease, and metabolic
Locations
-
Primary
Get directions
222 Berkeley Street, 12th Floor
Boston, MA 02116, US
Employees at Rhythm Pharmaceuticals Inc.
Updates
-
Earlier this year, Rhythm announced that the European Commission (EC) expanded the marketing authorization for our therapy to include children between 2 and younger than 6 years old with obesity due specific rare neuroendocrine diseases. You can read more here: https://bit.ly/3BKpA81 #Milestone #YearInReview
-
-
#ICYMI This fall Rhythm announced the publication of results from our Phase 3 study in children between the ages of 2 and younger than 6 years old with Bardet-Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency in the peer-reviewed journal The Lancet Diabetes & Endocrinology. Read our press release to learn more: https://bit.ly/40NKvkQ #YearInReview
-
-
In July, we were excited to announce the appointment of Alastair Garfield as our Chief Scientific Officer in July 2024! Al’s leadership and scientific expertise in the brain’s regulation of appetite and body weight have been instrumental in helping us further our mission to help improve the lives of patients living with rare neuroendocrine diseases. #YearInReview
-
-
In April 2024, Rhythm announced the publication of results from our investigational Phase 2 study in #hypothalamic #obesity in the Lancet Diabetes & Endocrinology. #YearInReview
-
-
This year Rhythm reached several important regulatory and market access milestones internationally, including in Germany, the UK, Italy and Spain. Achievements like this further our mission to help improve the lives of patients living with rare neuroendocrine diseases around the world. #YearInReview
-
Rhythm licensed an investigational oral small molecule melanocortin-4 receptor (MC4R) agonist, from LG Chem in January 2024. Learn more here: https://bit.ly/3D542Do #YearInReview
-
-
In 2024 Rhythm delivered more than 86 presentations at 24 international congresses to share research on hyperphagia and severe obesity caused by rare neuroendocrine diseases. Learn more about our research: https://bit.ly/4g7niyS #YearInReview
-
-
This year, Rhythm made tremendous progress in advancing our mission to transform the lives of patients living with rare neuroendocrine diseases. We now have almost 275 employees in 13 countries, and our product is now available to patients in more than 15 countries outside the U.S. #YearInReview
-
-
#ICYMI, Rhythm was named to @The Boston Globe’s Top Places to Work for the second year in a row! https://bit.ly/3ZpGwZc
-